Genentech announced a $750 million investment in a new drug delivery device facility at its Hillsboro, Oregon site, targeting expanded production capacity for delivery technologies used across its therapeutic programs. The company said the facility is expected to become operational soon. For the broader biotech sector, the investment signals continued emphasis on manufacturing scale and delivery-system throughput as a gating factor for translational speed—especially for modalities that depend on specialized delivery components. Manufacturing expansion also supports execution risk mitigation for future clinical programs, reducing supply bottlenecks when developers pivot from early trials into larger-scale studies and commercialization planning.